11. 854. Long-term Outcomes of Participants on F/TAF for Pre-Exposure Prophylaxis: Results for 144 Weeks of Follow-Up in the DISCOVER Trial. (4th December 2021) Authors: Ramgopal, Moti; Ruane, Peter; Shao, Yongwu; Ebrahimi, Ramin; Kintu, Alex; Carter, Christoph C; Das, Moupali; Baeten, Jared; Brinson, Cynthia; Shalit, Peter; Mounzer, Karam Journal: Open forum infectious diseases Issue: Volume 8(2021)Supplement 1 Page Start: S517 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Issue 6 (June 2019) Authors: Wohl, David A; Yazdanpanah, Yazdan; Baumgarten, Axel; Clarke, Amanda; Thompson, Melanie A; Brinson, Cynthia; Hagins, Debbie; Ramgopal, Moti N; Antinori, Andrea; Wei, Xuelian; Acosta, Rima; Collins, Sean E; Brainard, Diana; Martin, Hal Journal: Lancet Issue: Volume 6:Issue 6(2019) Page Start: e355 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Issue 4 (April 2017) Authors: Sax, Paul E; DeJesus, Edwin; Crofoot, Gordon; Ward, Douglas; Benson, Paul; Dretler, Robin; Mills, Anthony; Brinson, Cynthia; Peloquin, Julie; Wei, Xuelian; White, Kirsten; Cheng, Andrew; Martin, Hal; Quirk, Erin Journal: Lancet Issue: Volume 4:Issue 4(2017) Page Start: e154 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment. (1st May 2016) Authors: Wohl, David; Oka, Shinichi; Clumeck, Nathan; Clarke, Amanda; Brinson, Cynthia; Stephens, Jeffrey; Tashima, Karen; Arribas, Jose R.; Rashbaum, Bruce; Cheret, Antoine; Brunetta, Jason; Mussini, Cristina; Tebas, Pablo; Sax, Paul E.; Cheng, Andrew; Zhong, Lijie; Callebaut, Christian; Das, Moupali; Fo... Journal: Journal of acquired immune deficiency syndromes Issue: Volume 72:Number 1(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults. (1st November 2016) Authors: Gallant, Joel; Brunetta, Jason; Crofoot, Gordon; Benson, Paul; Mills, Anthony; Brinson, Cynthia; Oka, Shinichi; Cheng, Andrew; Garner, Will; Fordyce, Marshall; Das, Moupali; McCallister, Scott Journal: Journal of acquired immune deficiency syndromes Issue: Volume 73:Number 3(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide. (31st July 2018) Authors: Sax, Paul E.; DeJesus, Edwin; Crofoot, Gordon; Ward, Douglas; Benson, Paul; Dretler, Robin; Mills, Anthony; Brinson, Cynthia; Wei, Xuelian; Collins, Sean E.; Cheng, Andrew Journal: AIDS Issue: Volume 32:Number 12(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. Correction: Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study. Issue 5 (July 2017) Authors: Trottier, Benoît; Lake, Jordan E; Logue, Ken; Brinson, Cynthia; Santiago, Lizette; Brennan, Clare; Koteff, Justin A; Wynne, Brian; Hopking, Judy; Granier, Catherine; Aboud, Michael Journal: Antiviral therapy Issue: Volume 22:Issue 5(2017) Page Start: 459 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. (14th January 2015) Authors: Raffi, François; Rachlis, Anita; Brinson, Cynthia; Arasteh, Keikawus; Górgolas, Miguel; Brennan, Clare; Pappa, Keith; Almond, Steve; Granier, Catherine; Nichols, W. Garrett; Cuffe, Robert Liam; Jr, Joseph Eron; Walmsley, Sharon Journal: AIDS Issue: Volume 29:Number 2(2015) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study. Issue 4 (May 2017) Authors: Trottier, Benoît; Lake, Jordan E; Logue, Ken; Brinson, Cynthia; Santiago, Lizette; Brennan, Clare; Koteff, Justin A; Wynne, Brian; Hopking, Judy; Granier, Catherine; Aboud, Michael Journal: Antiviral therapy Issue: Volume 22:Issue 4(2017) Page Start: 295 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens. Issue 5 (September 2013) Authors: Mills, Anthony M.; Cohen, Calvin; DeJesus, Edwin; Brinson, Cynthia; Williams, Scott; Yale, Kitty L.; Ramanathan, Srini; Wang, Maggie H.; White, Kirsten; Chuck, Susan K.; Cheng, Andrew K. Journal: HIV clinical trials Issue: Volume 14:Issue 5(2013) Page Start: 216 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗